<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:01:57Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4999596" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4999596</identifier><datestamp>2016-09-07</datestamp><setSpec>ancltransneuro</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="brief-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Clin Transl Neurol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Clin Transl Neurol</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)2328-9503</journal-id>
      <journal-id journal-id-type="publisher-id">ACN3</journal-id>
      <journal-title-group>
        <journal-title>Annals of Clinical and Translational Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2328-9503</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4999596</article-id>
      <article-id pub-id-type="pmcid">PMC4999596</article-id>
      <article-id pub-id-type="pmc-uid">4999596</article-id>
      <article-id pub-id-type="pmid">27606346</article-id>
      <article-id pub-id-type="doi">10.1002/acn3.329</article-id>
      <article-id pub-id-type="publisher-id">ACN3329</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Brief Communication</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Neurologic syndrome associated with homozygous mutation at <styled-content style="fixed-case">MAG</styled-content> sialic acid binding site</article-title>
        <alt-title alt-title-type="left-running-head">R. H. Roda <italic>et al</italic>.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="acn3329-cr-0001" contrib-type="author" corresp="yes">
          <name>
            <surname>Roda</surname>
            <given-names>Ricardo H.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3329-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="acn3329-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="acn3329-cr-0002" contrib-type="author">
          <name>
            <surname>FitzGibbon</surname>
            <given-names>Edmond J.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3329-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="acn3329-cr-0003" contrib-type="author">
          <name>
            <surname>Boucekkine</surname>
            <given-names>Houda</given-names>
          </name>
          <xref ref-type="aff" rid="acn3329-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="acn3329-cr-0004" contrib-type="author">
          <name>
            <surname>Schindler</surname>
            <given-names>Alice B.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3329-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="acn3329-cr-0005" contrib-type="author">
          <name>
            <surname>Blackstone</surname>
            <given-names>Craig</given-names>
          </name>
          <xref ref-type="aff" rid="acn3329-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="acn3329-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Neurology</named-content>
        <named-content content-type="organisation-division">Neuromuscular Medicine</named-content>
        <institution>Johns Hopkins University School of Medicine</institution>
        <named-content content-type="city">Baltimore</named-content>
        <named-content content-type="country-part">Maryland</named-content>
      </aff>
      <aff id="acn3329-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Neurogenetics Branch</named-content>
        <institution>National Institute of Neurological Disorders and Stroke</institution>
        <institution>National Institutes of Health</institution>
        <named-content content-type="city">Bethesda</named-content>
        <named-content content-type="country-part">Maryland</named-content>
      </aff>
      <aff id="acn3329-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Laboratory of Sensorimotor Research</named-content>
        <institution>National Eye Institute</institution>
        <institution>National Institutes of Health</institution>
        <named-content content-type="city">Bethesda</named-content>
        <named-content content-type="country-part">Maryland</named-content>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Ricardo H. Roda, Department of Neurology, Johns Hopkins University School of Medicine, Meyer 5â119A, 600 N. Wolfe Street, Baltimore, MD 21287. Tel: 410â614â9402; Fax: 410â955â1961; Eâmail: <email>rroda1@jhmi.edu</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <volume>3</volume>
      <issue>8</issue>
      <issue-id pub-id-type="doi">10.1111/acn3.2016.3.issue-8</issue-id>
      <fpage>650</fpage>
      <lpage>654</lpage>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>1</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>26</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>5</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 American Neurological Association <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Published 2016. This article is a U.S. Government work and is in the public domain in the USA. <italic>Annals of Clinical and Translational Neurology</italic> published by Wiley Periodicals, Inc. on behalf of American Neurological Association</copyright-statement>
        <license license-type="creativeCommonsBy-nc-nd">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons AttributionâNonCommercialâNoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is nonâcommercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ACN3-3-650.pdf"/>
      <abstract id="acn3329-abs-0001">
        <title>Abstract</title>
        <p>The <italic><styled-content style="fixed-case">MAG</styled-content></italic> gene encodes myelinâassociated glycoprotein (<styled-content style="fixed-case">MAG</styled-content>), an abundant protein involved in axonâglial interactions and myelination during nerve regeneration. Several members of a consanguineous family with a clinical syndrome reminiscent of PelizaeusâMerzbacher disease and demyelinating leukodystrophy on brain <styled-content style="fixed-case">MRI</styled-content> were recently found to harbor a homozygous missense p.Ser133Arg <italic><styled-content style="fixed-case">MAG</styled-content></italic> mutation. Here, we report two brothers from a nonconsanguineous family afflicted with progressive cognitive impairment, neuropathy, ataxia, nystagmus, and gait disorder. Exome sequencing revealed the homozygous missense mutation p.Arg118His in <italic><styled-content style="fixed-case">MAG</styled-content></italic>. This Arg118 residue in immunoglobulin domain 1 is critical for sialic acid binding, providing a compelling mechanistic basis for disease pathogenesis.</p>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>Intramural Research Programs of the National Institute of Neurological Disorders and Stroke</funding-source>
        </award-group>
        <award-group>
          <funding-source>National Eye Institute</funding-source>
        </award-group>
        <award-group>
          <funding-source>National Institutes of Health</funding-source>
        </award-group>
        <award-group>
          <funding-source>Medical Research Scholars Program</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <page-count count="5"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>acn3329</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>August 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:26.08.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="acn3329-sec-0001">
      <title>Introduction</title>
      <p>Myelinâassociated glycoprotein (MAG; OMIM #159460) is a wellâknown protein involved in glialâaxon maintenance. It belongs to the SIGLEC superfamily of lectins that are able to bind sialic acid.<xref rid="acn3329-bib-0001" ref-type="ref">1</xref> MAG contains a large extracellular domain with five immunoglobulin (Ig) domains, a transmembrane domain, and a smaller cytoplasmic domain (Fig. <xref rid="acn3329-fig-0001" ref-type="fig">1</xref>A). It is enriched at periaxonal regions of myelin sheaths in peripheral as well as central nervous systems.<xref rid="acn3329-bib-0001" ref-type="ref">1</xref> Alternatively spliced mRNA transcripts generate long and short isoforms that differ in the size of the cytoplasmic region.<xref rid="acn3329-bib-0002" ref-type="ref">2</xref> MAG has been associated with at least two different activities: (1) as an inhibitor of axon growth in the CNS after injury<xref rid="acn3329-bib-0003" ref-type="ref">3</xref>, <xref rid="acn3329-bib-0004" ref-type="ref">4</xref> and (2) as an enhancer of axon radial growth at nodes of myelinated axons via phosphorylation of neurofilaments.<xref rid="acn3329-bib-0005" ref-type="ref">5</xref>, <xref rid="acn3329-bib-0006" ref-type="ref">6</xref>, <xref rid="acn3329-bib-0007" ref-type="ref">7</xref>, <xref rid="acn3329-bib-0008" ref-type="ref">8</xref> MAG interacts directly with axons of nerve cells through at least two different sites. One is centered within Ig domain 1, which is also critical for sialic acid binding, and the other is within Ig domains 4 and 5.<xref rid="acn3329-bib-0009" ref-type="ref">9</xref>, <xref rid="acn3329-bib-0010" ref-type="ref">10</xref>, <xref rid="acn3329-bib-0011" ref-type="ref">11</xref>
</p>
      <fig fig-type="Figure" xml:lang="en" id="acn3329-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Domain organization and disease mutations of the associated glycoprotein. (A) Structural domains of <styled-content style="fixed-case">MAG</styled-content> and mutations in our patients as well as previously reported mutations. Amino acid residue numbers are indicated (single letter amino acid code). (B) Family pedigree, with affected individuals harboring homozygous p.Arg118His mutations identified by blackâfilled squares. Alignments of the residues surrounding Arg118, showing conservation among species (C) and across other human sialoproteins (D). Amino acid residue numbers are indicated for human <styled-content style="fixed-case">MAG</styled-content>.</p>
        </caption>
        <graphic id="nlm-graphic-1" xlink:href="ACN3-3-650-g001"/>
      </fig>
      <p>Antibodies against MAG lead to a prevalent, adultâonset, autoimmune neuropathy associated with IgMâtype monoclonal antibodies (Mâprotein). Nerve biopsies typically show signs of myelin loss, and electrophysiological studies demonstrate nerve conduction slowing and increased distal latencies, consistent with demyelination.<xref rid="acn3329-bib-0012" ref-type="ref">12</xref>, <xref rid="acn3329-bib-0013" ref-type="ref">13</xref>, <xref rid="acn3329-bib-0014" ref-type="ref">14</xref>, <xref rid="acn3329-bib-0015" ref-type="ref">15</xref> Recently, whole exome evaluation of a large cohort of patients with genetically undiagnosed hereditary spastic paraplegia (HSP) raised the possibility that a homozygous c.1288T&gt;G (p.Cys430Gly) mutation in <italic>MAG</italic> might lead to HSP.<xref rid="acn3329-bib-0016" ref-type="ref">16</xref> A very recent report has supported this assignment, describing the clinical features of three siblings with a homozygous missense c.399C&gt;G (p.Ser133Arg) mutation in <italic>MAG</italic>.<xref rid="acn3329-bib-0017" ref-type="ref">17</xref> In both studies, patients were spastic, and syndromes with mutations in <italic>MAG</italic> leading to spasticity have been designated SPG75 (OMIM #616680). Notably, in the latter report patients also had hyporeflexia.</p>
    </sec>
    <sec id="acn3329-sec-0002">
      <title>Case Report</title>
      <p>Two brothers were referred to the NIH Neurogenetics Branch for progressive ataxia. They provided informed consent to participate in a clinical research protocol (00âNâ0043) approved by the NIH Combined Neuroscience Institutional Review Board. There are no other known affected family members in previous or later generations (Fig. <xref rid="acn3329-fig-0001" ref-type="fig">1</xref>B).</p>
      <p>Patient II.5 was clumsy as a child. However, during his teens and 20s he was an avid runner, until he noted difficulty with his legs and began tripping and falling frequently. In his 40s, he had to stop driving because of difficulty with his vision, and he started using a hearing aid for hearing loss. At age 48, he first came to our attention. On examination, his cognition was normal. He had circular nystagmus, worse in his right eye and less in downgaze. In addition, he exhibited saccadic dysmetria and saccadic pursuits. He had no optic neuropathy or maculopathy. He was diffusely hyporeflexive, with mild bilateral hipâflexor weakness and severe dorsiflexor weakness. Tone was normal, but Babinski sign was present bilaterally. Vibratory sensation was absent at the knees, and there was a distal, gradient impairment of pinprick sensation in the legs and feet. There was mild truncal ataxia, and he had a waddling gait.</p>
      <p>Patient II.2 was 54 years old upon initial evaluation at NIH. By history, he walked late (about 2 years of age), had frequent falls as a child, and was comparatively slow in physical activities as compared to his brothers. He was diagnosed with cerebral palsy at 14 years of age. He also suffered from mild learning difficulties in school. In his late 20s, he developed nystagmus and oscillopsia. By his late 40s, he was legally blind. He also suffered from a spastic bladder. Neuropsychologic testing revealed prominent impairments in attention and working memory. Ophthalmologic examination revealed central scotomas as well as bilateral optic atrophy (Fig. <xref rid="acn3329-fig-0002" ref-type="fig">2</xref>A), circular nystagmus, and severe vision loss (OD: Snellen: 20/500, OS: Snellen: 20/400). He was mildly dysarthric and mildly spastic, with preserved strength in the upper extremities but weakness in hip flexion and dorsiflexion more so than plantar flexion in the lower extremities. He was diffusely hyporeflexive throughout, but Babinski sign was present bilaterally. Romberg sign was present. Vibratory sensation was absent at the great toes, and there was truncal more so than appendicular dysmetria. The subject used a wheelchair, and gait was not tested.</p>
      <fig fig-type="Figure" xml:lang="en" id="acn3329-fig-0002" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Brain and retinal imaging of two subjects with homozygous p.Arg118His <italic><styled-content style="fixed-case">MAG</styled-content></italic> mutation. (A) Retinal images show optic disk atrophy in <styled-content style="fixed-case">II</styled-content>.2. (B) Sagittal brain T1âweighted <styled-content style="fixed-case">MRI</styled-content> images reveal diffuse atrophy in both patients, but more prominently in <styled-content style="fixed-case">II</styled-content>.2. (C) Transverse brain <styled-content style="fixed-case">MRI FLAIR</styled-content> images for <styled-content style="fixed-case">II</styled-content>.2 and <styled-content style="fixed-case">II</styled-content>.5 demonstrate global atrophy as well as white matter abnormalities in <styled-content style="fixed-case">II</styled-content>.5.</p>
        </caption>
        <graphic id="nlm-graphic-3" xlink:href="ACN3-3-650-g002"/>
      </fig>
      <p>In both patients, electrophysiological studies revealed an axonal sensorimotor polyneuropathy. There were also demyelinating features, with prolonged Fâwave and distal latencies (see Data S1). Exome analysis (see Data S2) of both affected subjects revealed a homozygous c.353G&gt;A (p.Arg118His) missense mutation in <italic>MAG</italic>; these results were confirmed through Sanger sequencing. This variant has been noted only once in 118,740 alleles, and in no homozygotes, in the database of the Exome Aggregation Consortium (ExAC; <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>) (December 2015). Exonâlevel oligo array CGH did not detect any deletions or duplications of the MAG gene in either brother (GeneDx, Gaithersburg, MD). This further suggests that they are homozygous for this allele, and that the inheritance is recessive despite the lack of consanguinity; we were unable to test either parent for additional confirmation. This missense mutation is within a highly conserved domain present in numerous sialoproteins as well as across various species for MAG itself (Fig. <xref rid="acn3329-fig-0001" ref-type="fig">1</xref>C and D); it is predicted to be damaging, with a score of 1.00 by PolyPhen 2.<xref rid="acn3329-bib-0018" ref-type="ref">18</xref> Prior commercial genetic testing including for mutations in <italic>SYNE1</italic> and <italic>ATM</italic> (Prevention Genetics, Marshfield, WI) did not reveal any pathogenic mutations. An additional screen for recessive causes of ataxia including <italic>ADCK3, AFG3L2, ANO10, APTX, ATM, FLVCR1, FXN, GRM1, MRE11A, MTPAP, POLG, SACS, SETX, SIL1, SYNE1, SYT14, TDP1,</italic> and <italic>TTPA</italic> did not reveal any pathogenic mutations (Athena Diagnostics, Marlborough, MA).</p>
      <p>Brain MRI of both patients showed global atrophy, without any obvious preference for the cerebellum (Fig. <xref rid="acn3329-fig-0002" ref-type="fig">2</xref>B and C). In patient II.5, discrete white matter lesions were evident on FLAIR sequences, reminiscent of those previously reported in patients with the p.Ser133Arg mutation in MAG.<xref rid="acn3329-bib-0017" ref-type="ref">17</xref> Skin biopsies performed to evaluate epidermal nerve fibers for morphological abnormalities revealed only nonspecific axonal swellings (data not shown).</p>
    </sec>
    <sec id="acn3329-sec-0003">
      <title>Discussion</title>
      <p>We identified two brothers with the same homozygous p.Arg118His mutation in Ig domain 1 of MAG. This is a highly conserved residue critical for sialic acid binding.<xref rid="acn3329-bib-0008" ref-type="ref">8</xref>, <xref rid="acn3329-bib-0011" ref-type="ref">11</xref> Although antibodies against MAG have been widely described as causing a wellâcharacterized autoâimmune neuropathy, there have only been two reports of patients with homozygous <italic>MAG</italic> mutations.<xref rid="acn3329-bib-0016" ref-type="ref">16</xref>, <xref rid="acn3329-bib-0017" ref-type="ref">17</xref> The two patients described here appear similar in presentation to those described previously. Their predominant symptoms are ataxia, nystagmus, mild distal weakness and, in one affected brother, cognitive difficulties.</p>
      <p>The results here and those of Lossos et al.<xref rid="acn3329-bib-0017" ref-type="ref">17</xref> suggest that homozygous p.Arg118His and p.Ser133Arg mutations both lead to a loss of MAG protein function in peripheral nervous tissue. Sural nerve biopsy in one patient with the p.Ser133Arg mutation did not reveal significant morphological alterations, other than rare, illâformed onionâbulb structures, but there was a significant decrease in MAG levels, and the p.Ser133Arg mutation decreased protein stability.<xref rid="acn3329-bib-0017" ref-type="ref">17</xref> We similarly did not note significant morphological abnormalities other than axonal swellings in epidermal nerve biopsies from our patients. Previous studies have shown that mutating Arg118 to either Ala or Asp abolishes its sialic acid binding activity.<xref rid="acn3329-bib-0011" ref-type="ref">11</xref> We suspect that this loss of function could underlie the symptoms in our patients, though we cannot rule out the possibility of decreased MAG protein stability as well.</p>
      <p>Clinical findings, global brain atrophy and FLAIR abnormalities on MRI, and optic nerve atrophy on fundoscopy are also suggestive of central nervous system disease. Interestingly, myelination still occurs in the absence of MAG in mice.<xref rid="acn3329-bib-0019" ref-type="ref">19</xref>, <xref rid="acn3329-bib-0020" ref-type="ref">20</xref> However, while compaction of myelin is normal, the organization of the periâaxonal spaces is not,<xref rid="acn3329-bib-0019" ref-type="ref">19</xref> and these abnormalities extend to the optic nerves of examined mice.<xref rid="acn3329-bib-0020" ref-type="ref">20</xref> Patient II.2 had significant optic atrophy on examination (Fig. <xref rid="acn3329-fig-0002" ref-type="fig">2</xref>A), suggesting that there is some correlation between <italic>Mag</italic> null mouse models and patients with lossâofâfunction <italic>MAG</italic> mutations. Similarly, a lateâonset axonal neuropathy is seen in aged <italic>Mag</italic>âdeficient mice, reminiscent of that seen in our patients.<xref rid="acn3329-bib-0006" ref-type="ref">6</xref>
</p>
      <p>To date, mutations in Ig 1 and Ig 5 domains as well as between Ig 1 and Ig 2 have been identified. Although there are not enough mutations to determine whether hot spots exist, it is intriguing that Ig 1 and Ig 4,5 domains in fact serve different functions.<xref rid="acn3329-bib-0008" ref-type="ref">8</xref> Studies in mice have also demonstrated an increase in NâCAM (another adhesion molecule) mRNA expression in the absence of MAG, suggesting the presence of a compensatory mechanism that might ameliorate what could otherwise be a more severe presentation. However, a more complete pathological assessment of the effects of these mutations in central glia is still required. Recessive <italic>MAG</italic> mutations should be considered as a possible cause of any unsolved ataxia and neuropathy syndromes, and new cases should shed further light on pathogenic mechanisms.</p>
    </sec>
    <sec id="acn3329-sec-0005">
      <title>Conflict of Interest</title>
      <p>None declared.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data">
        <caption>
          <p>
<bold>Data S1.</bold> Description of methods used for exome analysis and list of genes screened.</p>
        </caption>
        <media xlink:href="ACN3-3-650-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>
<bold>Data S2.</bold> Electromyography and nerve conduction data.</p>
        </caption>
        <media xlink:href="ACN3-3-650-s002.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="acn3329-sec-0004">
      <title>Acknowledgments</title>
      <p>We thank Elizabeth Hartnett for help with patient scheduling and the Johns Hopkins Hospital Cutaneous Nerve Laboratory for performing the biopsy analysis. We also thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison; a list of contributing groups is available at <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/about">http://exac.broadinstitute.org/about</ext-link>.</p>
    </ack>
    <ref-list content-type="cited-references" id="acn3329-bibl-0001">
      <title>References</title>
      <ref id="acn3329-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0001">
<string-name>
<surname>Quarles</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Myelinâassociated glycoprotein (MAG): past, present and beyond</article-title>. <source>J Neurochem</source>
<year>2007</year>;<volume>100</volume>:<fpage>1431</fpage>â<lpage>1448</lpage>.<pub-id pub-id-type="pmid">17241126</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0002">
<string-name>
<surname>Salzer</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Holmes</surname>
<given-names>WP</given-names>
</string-name>, <string-name>
<surname>Colman</surname>
<given-names>DR</given-names>
</string-name>. <article-title>The amino acid sequences of the myelinâassociated glycoproteins: homology to the immunoglobulin gene superfamily</article-title>. <source>J Cell Biol</source>
<year>1987</year>;<volume>104</volume>:<fpage>957</fpage>â<lpage>965</lpage>.<pub-id pub-id-type="pmid">2435742</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0003">
<string-name>
<surname>Mukhopadhyay</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Doherty</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Walsh</surname>
<given-names>FS</given-names>
</string-name>, et al. <article-title>A novel role for myelinâassociated glycoprotein as an inhibitor of axonal regeneration</article-title>. <source>Neuron</source>
<year>1994</year>;<volume>13</volume>:<fpage>757</fpage>â<lpage>767</lpage>.<pub-id pub-id-type="pmid">7522484</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0004">
<string-name>
<surname>McKerracher</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>David</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>DL</given-names>
</string-name>, et al. <article-title>Identification of myelinâassociated glycoprotein as a major myelinâderived inhibitor of neurite growth</article-title>. <source>Neuron</source>
<year>1994</year>;<volume>13</volume>:<fpage>805</fpage>â<lpage>811</lpage>.<pub-id pub-id-type="pmid">7524558</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0005">
<string-name>
<surname>Yin</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Crawford</surname>
<given-names>TO</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>JW</given-names>
</string-name>, et al. <article-title>Myelinâassociated glycoprotein is a myelin signal that modulates the caliber of myelinated axons</article-title>. <source>J Neurosci</source>
<year>1998</year>;<volume>18</volume>:<fpage>1953</fpage>â<lpage>1962</lpage>.<pub-id pub-id-type="pmid">9482781</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0006">
<string-name>
<surname>Weiss</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Luciano</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Quarles</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Nerve conduction abnormalities in aging mice deficient for myelinâassociated glycoprotein</article-title>. <source>Muscle Nerve</source>
<year>2001</year>;<volume>24</volume>:<fpage>1380</fpage>â<lpage>1387</lpage>.<pub-id pub-id-type="pmid">11562920</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0007">
<string-name>
<surname>Garcia</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Lobsiger</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>SB</given-names>
</string-name>, et al. <article-title>NFâM is an essential target for the myelinâdirected âoutsideâinâ signaling cascade that mediates radial axonal growth</article-title>. <source>J Cell Biol</source>
<year>2003</year>;<volume>163</volume>:<fpage>1011</fpage>â<lpage>1020</lpage>.<pub-id pub-id-type="pmid">14662745</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0008">
<string-name>
<surname>Nguyen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mehta</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Conant</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Axonal protective effects of the myelinâassociated glycoprotein</article-title>. <source>J Neurosci</source>
<year>2009</year>;<volume>29</volume>:<fpage>630</fpage>â<lpage>637</lpage>.<pub-id pub-id-type="pmid">19158290</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0009">
<string-name>
<surname>Kelm</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pelz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schauer</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Sialoadhesin, myelinâassociated glycoprotein and CD22 define a new family of sialic acidâdependent adhesion molecules of the immunoglobulin superfamily</article-title>. <source>Curr Biol</source>
<year>1994</year>;<volume>4</volume>:<fpage>965</fpage>â<lpage>972</lpage>.<pub-id pub-id-type="pmid">7533044</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0010">
<string-name>
<surname>Cao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Qiu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Domeniconi</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>The inhibition site on myelinâassociated glycoprotein is within Igâdomain 5 and is distinct from the sialic acid binding site</article-title>. <source>J Neurosci</source>
<year>2007</year>;<volume>27</volume>:<fpage>9146</fpage>â<lpage>9154</lpage>.<pub-id pub-id-type="pmid">17715351</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0011">
<string-name>
<surname>Tang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>DeBellard</surname>
<given-names>ME</given-names>
</string-name>, et al. <article-title>Myelinâassociated glycoprotein interacts with neurons via a sialic acid binding site at ARG118 and a distinct neurite inhibition site</article-title>. <source>J Cell Biol</source>
<year>1997</year>;<volume>138</volume>:<fpage>1355</fpage>â<lpage>1366</lpage>.<pub-id pub-id-type="pmid">9298990</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0012">
<string-name>
<surname>Steck</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Meier</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Demyelinating neuropathy and monoclonal IgM antibody to myelinâassociated glycoprotein</article-title>. <source>Neurology</source>
<year>1983</year>;<volume>33</volume>:<fpage>19</fpage>â<lpage>23</lpage>.<pub-id pub-id-type="pmid">6184645</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0013">
<string-name>
<surname>Steck</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Dellagi</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Peripheral neuropathy associated with monoclonal IgM autoantibody</article-title>. <source>Ann Neurol</source>
<year>1987</year>;<volume>22</volume>:<fpage>764</fpage>â<lpage>767</lpage>.<pub-id pub-id-type="pmid">2829706</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0014">
<string-name>
<surname>Steck</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Stalder</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Renaud</surname>
<given-names>S</given-names>
</string-name>. <article-title>Antiâmyelinâassociated glycoprotein neuropathy</article-title>. <source>Curr Opin Neurol</source>
<year>2006</year>;<volume>19</volume>:<fpage>458</fpage>â<lpage>463</lpage>.<pub-id pub-id-type="pmid">16969155</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0015">
<string-name>
<surname>Kaku</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>England</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Sumner</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelinâassociated glycoprotein and sulphated glucuronyl paragloboside</article-title>. <source>Brain</source>
<year>1994</year>;<volume>117</volume>:<fpage>941</fpage>â<lpage>947</lpage>.<pub-id pub-id-type="pmid">7953603</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0016">
<string-name>
<surname>Novarino</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fenstermaker</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Zaki</surname>
<given-names>MS</given-names>
</string-name>, et al. <article-title>Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders</article-title>. <source>Science</source>
<year>2014</year>;<volume>343</volume>:<fpage>506</fpage>â<lpage>511</lpage>.<pub-id pub-id-type="pmid">24482476</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0017">
<string-name>
<surname>Lossos</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Elazar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lerer</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Myelinâassociated glycoprotein gene mutation causes PelizaeusâMerzbacher diseaseâlike disorder</article-title>. <source>Brain</source>
<year>2015</year>;<volume>138</volume>:<fpage>2521</fpage>â<lpage>2536</lpage>.<pub-id pub-id-type="pmid">26179919</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0018">
<string-name>
<surname>Adzhubei</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Peshkin</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>A method and server for predicting damaging missense mutations</article-title>. <source>Nat Methods</source>
<year>2010</year>;<volume>7</volume>:<fpage>248</fpage>â<lpage>249</lpage>.<pub-id pub-id-type="pmid">20354512</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0019">
<string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tropak</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Gerlai</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Myelination in the absence of myelinâassociated glycoprotein</article-title>. <source>Nature</source>
<year>1994</year>;<volume>369</volume>:<fpage>747</fpage>â<lpage>750</lpage>.<pub-id pub-id-type="pmid">7516497</pub-id></mixed-citation>
      </ref>
      <ref id="acn3329-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="acn3329-cit-0020">
<string-name>
<surname>Montag</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Giese</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Bartsch</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Mice deficient for the myelinâassociated glycoprotein show subtle abnormalities in myelin</article-title>. <source>Neuron</source>
<year>1994</year>;<volume>13</volume>:<fpage>229</fpage>â<lpage>246</lpage>.<pub-id pub-id-type="pmid">7519026</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>